Equipoise the Horse Steroid – Side Effects & Properties

Member Access Required

Already a member? Sign In

Timeline

00:00

Equipoise is introduced as boldenone undecylenate, used by people and by horses. The opening frames it as an old steroid with a long and influential history.

01:52

The history section cites patenting in 1949 and early pharmaceutical experimentation with ester tails. The narrative explains how human marketing faded while veterinary use expanded rapidly.

06:00

Chemical structure is compared to testosterone, highlighting a double bond change in the ring. The long half life is emphasized as a defining feature for users planning cycles.

08:19

Side effects shift toward estrogen discussion, noting boldenone is milder yet still active. The segment warns that gynecomastia and water retention can still appear with use.

10:25

Stacking with testosterone is described as common, and SHBG effects are said to raise free testosterone. That combination is framed as the reason estrogenic symptoms can worsen unexpectedly.

12:03

Androgenic problems are reviewed, including acne, hair loss patterns, and prostate symptom flare ups. The discussion also calls suppression of the gonadal axis especially severe with pairing.

15:15

Polycythemia risk is explained through erythrocytosis and rising red blood cell production signals. The warning highlights that thicker blood can become a dangerous downstream complication.

16:25

Kidney toxicity is emphasized, with focal segmental glomerulosclerosis named as a recurring diagnosis. The transcript claims accelerated kidney damage appears more often with this compound.

17:43

Cardiovascular disease is discussed with mechanisms like volume expansion and blood pressure elevation. Plaque progression toward myocardial infarction is presented as a plausible long term threat.

18:40

Left ventricular hypertrophy is described as a structural remodeling seen with chronic exposure over years. The segment argues enlarged skeletal muscle feels good while an enlarged heart does not.

19:03

The closing urges caution and personal responsibility, acknowledging steroids can feel amazing initially. It warns that irreversible injury to heart and kidneys can follow careless use.

Video Summary

Equipoise is introduced as boldenone undecylenate, a long acting injectable anabolic steroid. The transcript calls it a grandfather steroid, with origins patented in the late 1940s. Early manufacturers are described as experimenting with ester tails to prolong release and effects. A human product is mentioned in the 1960s, followed by discontinuation for human use by the late 1970s. The narrative then shifts to a veterinary market, where Equipoise is used widely in horses. Horse owners are quoted as saying appetite rises and the animal seems eager to race. That history is used to explain why the compound became famous in bodybuilding culture.

The pharmacology segment explains that boldenone differs from testosterone by a double bond in the ring structure. A long half life is emphasized, with numbers like fourteen to twenty one days discussed. The transcript highlights a surprising similarity to Dianabol, calling it injectable D bol by structure. Boldenone is described as less estrogenic than testosterone, yet estrogenic problems still appear in practice. Gynecomastia, water retention, and mood changes are mentioned as possible outcomes with use. A key warning is that Equipoise can increase testosterone by altering sex hormone binding globulin dynamics. Because most users stack Test and EQ, the discussion expects amplified estrogen side effects from the combination.

The side effect section stresses that Test and EQ together can worsen acne, balding, and prostate symptoms. Suppression of the hypothalamic pituitary gonad axis is described as massive with this pairing. Red blood cell increases are emphasized, linking erythrocytosis to polycythemia in susceptible users. Kidney toxicity is highlighted, with focal segmental glomerulosclerosis named as a pattern seen clinically. Cardiovascular harm is discussed through higher volume, hypertension, and plaque progression toward heart attack. Left ventricular hypertrophy is presented as a real finding after years of poorly managed exposure. The closing warns that the initial good feelings can be followed by irreversible heart and kidney damage.

Drug Callouts

Boldenone undecylenate (Equipoise)

Boldenone undecylenate is an injectable anabolic steroid ester derived from the boldenone molecule. The transcript describes it as a long acting veterinary drug commonly called Equipoise.

Testosterone

Testosterone is the primary endogenous androgen hormone and a common base steroid in many cycles. The transcript repeatedly references stacking Test with EQ as the typical real world pattern.

Methandrostenolone (Dianabol)

Methandrostenolone is an oral anabolic steroid historically known as Dianabol or D bol. The transcript says boldenone’s core structure mirrors Dianabol, calling it injectable D bol.

Aromatase inhibitors

Aromatase inhibitors are medicines that reduce conversion of androgens into estradiol in tissues. The transcript mentions using aromatase inhibitors when Test and EQ worsen estrogenic issues.

Selective estrogen receptor modulators (SERMs)

Selective estrogen receptor modulators are drugs that block or modulate estrogen receptors in specific tissues. The transcript references SERMs as another tool used when estrogenic symptoms occur.

Condition Callouts

Gynecomastia

Gynecomastia is benign growth of glandular breast tissue in males from hormonal signaling changes. The transcript warns gynecomastia can still occur, especially when Test and EQ are stacked.

Polycythemia

Polycythemia is an abnormally high red blood cell mass that can thicken blood circulation. The transcript links Equipoise, Deca, and testosterone to polycythemia through erythrocytosis.

Anabolic steroid induced hypogonadism

Anabolic steroid induced hypogonadism is persistent suppression of the HPG axis after steroid exposure. The transcript describes massive HPG suppression when testosterone is combined with Equipoise.

Focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis is scarring of kidney filtering units that can cause protein loss. The transcript names FSGS as a recurring kidney disease pattern seen in steroid users.

Chronic kidney disease

Chronic kidney disease is long term loss of kidney function measured by filtration and injury markers. The transcript cautions that Equipoise may accelerate kidney damage compared with other steroids.

Hypertension

Hypertension is persistently elevated blood pressure that increases stroke and heart strain over time. The transcript describes significant hypertension when testosterone use is combined with Equipoise.

Left ventricular hypertrophy

Left ventricular hypertrophy is thickening of the heart’s left ventricle wall from chronic overload. The transcript warns LVH can develop over years of testosterone and Equipoise exposure.

Myocardial infarction

Myocardial infarction is heart muscle injury caused by blocked coronary blood flow and clotting. The transcript links plaque progression and vascular stress to an increased heart attack threat.

Male pattern baldness

Male pattern baldness is androgen driven scalp hair miniaturization that follows genetic vulnerability. The transcript says hair loss can worsen when testosterone and Equipoise are paired in cycles.

Acne

Acne is an inflammatory skin condition involving clogged follicles and bacterial overgrowth. The transcript states acne commonly worsens when Test and EQ are used together.

Key Takeaways

Equipoise is described as boldenone undecylenate with a very long half life.
The transcript claims most users stack testosterone with Equipoise in practice.
Polycythemia risk is emphasized through erythrocytosis and rising red blood cells.
Kidney toxicity is highlighted, including focal segmental glomerulosclerosis as a concern.
Long term use is linked to left ventricular hypertrophy and myocardial infarction risk.